Learning from the proteasome: how to fine-tune cancer immunotherapy
Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class...
| Những tác giả chính: | , , |
|---|---|
| Định dạng: | Journal article |
| Ngôn ngữ: | English |
| Được phát hành: |
Cell Press
2017
|
| _version_ | 1826282561577418752 |
|---|---|
| author | Vigneron, N Abi Habib, J Van den Eynde, B |
| author_facet | Vigneron, N Abi Habib, J Van den Eynde, B |
| author_sort | Vigneron, N |
| collection | OXFORD |
| description | Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The success and safety of cancer immunotherapy strategies depends on the nature of the antigens recognized by the targeted T cells, their strict tumor specificity, and whether tumors and antigen-presenting cells can efficiently process the peptide. We review here the nature of the tumor antigens and their potential for the development of immunotherapeutic strategies. We also discuss the importance of proteasome in the production of these peptides in the context of immunotherapy and therapeutic cancer vaccines. |
| first_indexed | 2024-03-07T00:45:43Z |
| format | Journal article |
| id | oxford-uuid:84939cf6-9539-48e5-99b0-1595e8f40b2d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:45:43Z |
| publishDate | 2017 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:84939cf6-9539-48e5-99b0-1595e8f40b2d2022-03-26T21:51:58ZLearning from the proteasome: how to fine-tune cancer immunotherapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:84939cf6-9539-48e5-99b0-1595e8f40b2dEnglishSymplectic Elements at OxfordCell Press2017Vigneron, NAbi Habib, JVan den Eynde, BCancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The success and safety of cancer immunotherapy strategies depends on the nature of the antigens recognized by the targeted T cells, their strict tumor specificity, and whether tumors and antigen-presenting cells can efficiently process the peptide. We review here the nature of the tumor antigens and their potential for the development of immunotherapeutic strategies. We also discuss the importance of proteasome in the production of these peptides in the context of immunotherapy and therapeutic cancer vaccines. |
| spellingShingle | Vigneron, N Abi Habib, J Van den Eynde, B Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title | Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title_full | Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title_fullStr | Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title_full_unstemmed | Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title_short | Learning from the proteasome: how to fine-tune cancer immunotherapy |
| title_sort | learning from the proteasome how to fine tune cancer immunotherapy |
| work_keys_str_mv | AT vigneronn learningfromtheproteasomehowtofinetunecancerimmunotherapy AT abihabibj learningfromtheproteasomehowtofinetunecancerimmunotherapy AT vandeneyndeb learningfromtheproteasomehowtofinetunecancerimmunotherapy |